Christine Brezden-Masley, MD, PhD, FRCPC
Associate Professor of Medicine, University of Toronto; Director, Marvelle Koffler Breast Centre; Medical Director, Cancer Program at Sinai Health, Toronto, ON, Canada. President, Canadian Cardiac Oncology Network
Dr. Christine Brezden-Masley is a practicing Medical Oncologist and the Director of the Marvelle Koffler Breast Centre at Mount Sinai Hospital. She is the Medical Director of the Cancer Program at Sinai Health System. She obtained her PhD in Medical Biophysics at Princess Margaret Hospital in Toronto and her Medical Degree from the University of Toronto. She is currently an Associate Professor at the University of Toronto, an Associate Scientist at the Lunenfeld Tanenbaum Research Institute, and an Associate Scientist at the Li Ka Shing Knowledge Institute.Read More...
She is the founder of the COMET (Community Oncologists of Metropolitan Toronto) Clinical Trials Consortium, a web-based virtual network promoting cancer clinical trials throughout the Toronto Region. She treats both Breast and GI (colorectal and gastric cancers) malignancies and these are the major areas of her clinical research. Her main area of clinical research is cardiotoxicity from cancer therapy and has been the Co-Chair of the Annual Canadian Cardio-Oncology Network meeting, a collaborative national meeting improving cardiac heath in cancer patients. She is currently the President of the Canadian Cardio-Oncology Network and the Co-Chair of the 2020 Global Cardio-Oncology Summit.
Dinesh Thavendiranathan, MD, SM, FRCPC, FASE
Director, Ted Rogers Program in Cardiotoxicity Prevention, Toronto General Hospital, Associate Professor of Medicine; University of Toronto, Toronto, ON, Canada, Toronto General Hospital
Dr. Paaladinesh Thavendiranathan MD, SM, FRCPC, FASE is a cardiologist at the Toronto General Hospital, University of Toronto. He is an Associate Professor of Medicine and a Clinician Investigator. His training was in advanced cardiovascular imaging and his current clinical practice involves work with cardiac MRI, CT, and echocardiography. He is the Director of the Ted Rogers Program in Cardiotoxicity Prevention which focuses on cardiac toxicity from systemic therapies including cancer therapy. His research focus is in the use of advanced cardiac imaging techniques for detection and management of cardiac toxicity.
Anne Blaes, MD, MS
Associate Professor, University of Minnesota; Hematology/Oncology, Section Head, Medical Oncology, Director of Cancer Survivorship Services and Translational Research, Masonic Cancer Center
Dr. Anne Blaes is an Associate Professor in the Division of Hematology and Oncology at the University of Minnesota. She is the section head of Medical Oncology within this division and is Director of Cancer Survivorship Services and Translational Research within the Masonic Cancer Center. She is an active medical oncologist with a special interest in the late effects of cancer therapy, particularly in the area of cardio-oncology.Read More...
Her research focuses on designing and implementing strategies to help prevent the long term complications of treatments in our cancer survivors, particularly in the areas of cardiovascular health, secondary cancers and quality of life. She is the current Chair for the American Society of Clinical Oncology’s Cancer Survivorship Committee, a member of the Executive Board for the Global Cardiooncology Society, and an active member of the ALLIANCE for Cancer Clinical Trials.
Joseph Carver, MD
Bernard Fishman Clinical Professor of Medicine; Chief Operating Officer, Abramson Family Cancer Research Institute; Chief of Staff, Abramson Cancer Center of the University of Pennsylvania, Philadelphia, PA, USA
Dr. Joseph Carver is the Bernard Fishman Clinical Professor of Medicine at the Abramson Cancer Center of the University of Pennsylvania, the Chief Operating Officer of the Abramson Family Cancer Research Institute of the Abramson Cancer Center of the University of Pennsylvania and the Chief of Staff of the Abramson Cancer Center. His clinical practice is in the sub-specialty of cardio-oncology. He was the recipient of the IS Ravdin Master Clinician Award at Penn in 2012. He is one of the Founding Editors of Cardio-oncology Journal.
Susan Dent, MD, FRCPC
Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology, Duke University, Durham, NC, USA; Founder & Past-President, Canadian Cardiac Oncology Network
Dr. Susan Dent is a Professor of Medicine, Associate Director of Breast Cancer Research and Co-Director of Cardio-Oncology at Duke University. She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the Canadian Cancer Trials Group. Her areas of research interest include breast cancer, and treatment related toxicities with a particular interest in cardiotoxicity.Read More...
She is the Founder and past-president of the Canadian Cardiac Oncology Network (CCON), an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity. She is Vice President and a member of the Board of Directors of the International Cardio-Oncology Society (ICOS) and Chair of the Global Cardio-Oncology Summit (GCOS) Advisory Committee.
Michael G. Fradley, MD
Associate Professor of Medicine, University of South Florida; Cardiologist and Director, Cardio-Oncology Program, Moffitt Cancer Center and Research Institute, Tampa, FL, USA, Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Dr. Fradley is an Associate Professor of Medicine at the University of South Florida with a joint appointment at Moffitt Cancer Cente. He is the director of the combined Moffitt Cancer Center-University of South Florida Cardio-Oncology program. He earned his B.S at Yale University and his MD degree at the Johns Hopkins University School of Medicine. He remained at Johns Hopkins for internal medicine residency and then went on to complete fellowships in both cardiology and clinical cardiac electrophysiology at Massachusetts General Hospital.Read More...
His research focuses on all aspects of cardio-oncology, however as a trained electrophysiologist, Dr. Fradley has particular interest in the diagnosis and management of arrhythmic complications associated with traditional and novel cancer therapies. He has co-authored numerous articles in the field of cardio-oncology. He is also actively involved in undergraduate and graduate medical education mentoring medical students, residents and fellows. He developed and serves as the program director for cardio-oncology fellowship at the University of South Florida and Moffitt Cancer Center. He is the co-director of the biomedical research tract in the Scholarly Concentrations Program at the University of South Florida, Morsani College of Medicine. He is also the medical director for the Harvey Simulation Elective and teaches the cardiovascular pathophysiology course for the second year medical students.
Daniel J. Lenihan, MD, FACC
Professor of Medicine; Director, Cardio-Oncology Center of Excellence, Washington University Medical Center, St Louis, MO, USA. President, International Cardio-Oncology Society
Dr. Lenihan, has been active in cardio-oncology and heart failure, for over 25 years. The main focus of these efforts have included hemodynamic assessments, angiogenic growth factor response, novel cardiac biomarkers as well as optimal methods to prevent or detect heart failure at the earliest stage possible in patients undergoing treatment for cancer. He has previously held positions at MD Anderson Cancer Center in Houston and Vanderbilt University prior to becoming the Director, Cardio-Oncology Center of Excellence at Washington University in St Louis in Sept 2017.Read More...
His current research projects include early phase clinical trials in cardio-oncology, heart failure and amyloidosis. He is the PI of the PROTECT study looking at cardiac safety in patients undergoing proteasome inhibitor treatment for relapsed multiple myeloma that was published in the Journal of Clinical Oncology (JCO) in 2019 and recently completed the PREDICT study, a large multicenter prospective study examining the role of cardiac biomarkers for the detection of cardiotoxicity during anthracycline based therapy. He is also intimately involved in the latest treatment trials for cardiac amyloidosis. Dr. Lenihan is at the forefront of concerted efforts to develop a viable Cardio-Oncology fellowship training program and continues to foster collaboration among a host of colleagues both regionally, nationally, and throughout the world. He is the current president of the International Cardio-Oncology Society (ICOS), a professional association whose primary goal is to eliminate cardiac disease as a barrier to effective cancer therapy.
Teresa Lopez-Fernandez, MD
Noninvasive Cardiologist, Cardiac Imaging Unit and Cardio-oncology Unit, La Paz University Hospital, Madrid, Spain
Teresa López-Fernández, MD, leads the Cardiac Imaging Unit and Cardio-Oncology Unit, at La Paz University Hospital, Madrid, Spain. Her clinical and research focus include mechanisms, diagnosis and treatment of cardiac complications of cancer therapies. Her clinical cardiac imaging expertise includes advanced training in echocardiography, 3D echocardiography, and stress echocardiography. Dr. López-Fernández is the president of the Imaging Association of the Spanish Society of Cardiology and the coordinator of the Spanish Cardio oncology working group.Read More...
She is also the secretary of the ESC council of cardio-oncology. Dr. López-Fernández obtained her degree in Medicine and Surgery in 1996 (Universidad Complutense de Madrid (Spain), followed by an I.R. Residence in Cardiology in the Hospital Fundación Jiménez Díaz, in Madrid (1997-2002). In 2004, she obtained her accreditation in advanced Echocardiography by the Spanish Society ofCardiology. Dr. López-Fernández completed additional certifications in Adult Transthoracic Echocardiography (2013 and 2019) and Adult Transesophageal Echocardiography (2014 and 2020) by the European Society of Cardiology.
Alexander Lyon, MA, BM, BCh, PhD, FRCP, FHFA
Senior Lecturer in Cardiology, Imperial College London; Consultant Cardiologist & Clinical Lead for Cardio-Oncology Service, Royal Brompton Hospital, London, United Kingdom. President, British Cardio-Oncology Society
Dr. Alexander Lyon is a Senior Lecturer in Cardiology at Imperial College London and a Consultant Cardiologist at the Royal Brompton Hospital. His clinical interests are in the field of heart failure, cardio-oncology including chemotherapy cardiomyopathy and the cardiovascular complications of modern cancer therapies, Takotsubo syndrome and the effects of major stresses of the heart, and the development of novel therapeutics including gene therapy for chronic heart failure. Alex has published 137 scientific papers in peer-reviewed journals, several book chapters in cardiology textbooks, he is an associate editor of the European Journal of Heart Failure, and his H-index is 35.Read More...
Alex is the clinical lead for the Cardio-Oncology service at the Royal Brompton Hospital since 2011, specialising in surveillance and cardioprotection from modern cancer drugs, risk stratification and treatment of all cardiac complications of cancer treatment. Alex is the current president of the British Cardio-Oncology Society, treasurer of the new European Society of Cardiology (ESC) Council of Cardio-Oncology and he is the cardiology advisor to the charity Macmillan Cancer. Alex is a co-investigator of the first Leducq Cardio-Oncology Transatlantic Research Network funded from 2020-2025. Alex is on the board of the Heart Failure Association of the ESC, and he is the chair of the Heart Failure Association Cardio-Oncology Study Group. He is a co-author of the ESC Position Statement on Cardio-Oncology, the ESC Cardio-Oncology Council article on the setting up and delivery of Cardio-Oncology services and the 2020 ESMO guidelines on the management of cardiac diseases in cancer patients. He is a member of the International Cardio-Oncology Society and Alex was co-chair of the 2017 Global Cardio-Oncology Summit which hosted 325 specialists from 33 countries at the Royal College of Physicians in London in September 2017.
Sebastian Szmit, MD, PhD
Associate Professor of Medicine; Cardiologist & Specialist of Internal Medicine, Centre of Postgraduate Medical Education, Otwock, Warsaw, Poland
Sebastian Szmit graduated from the Military Medical Academy in Poland, worked as an internal medicine doctor in the Emergency Department, Internal Diseases and Cardiology Clinic and Oncology Clinic in the Military Institute of Medicine (2003-2012) and in the Laboratory of Exercise Tests in the Central Hospital of the Medical University of Warsaw (2007-2012). From 2012 he is the Cardio-Oncology Consultant and the Chief of the Laboratory of Cardio-Pulmonary Exercise Testing in the Department of Pulmonary Circulation, Thromboembolic Diseases and Cardiology, Centre of Postgraduate Medical Education at the European Health Centre in Otwock.Read More...
Sebastian Szmit is the scientific director of the course entitled "Oncology in Cardiology" - obligatory training within specialty program in cardiology in Poland. Sebastian Szmit was appointed the executive editor of the Task Force of National Consultants in Cardiology and Clinical Oncology, to develop the first two Polish documents of Recommendations on cardiologic safety of patients with breast cancer (published in 2010) and lung cancer (published in 2012). He is Co-author of two educational books: "Hypertension-oncology: arterial hypertension in cancer disease" and "Cardiovascular complications in cancer patients" published in 2018 under auspices of the Polish Society of Clinical Oncology. From 2016 Sebastian Szmit is the Research Coordinator of the Cardio-Oncology Section of the Polish Lymphoma Research Group as well as the President of the Onco-Cardiology Team within the Polish National Oncology Network. Sebastian Szmit is the National Coordinator of two international academic trials: - Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end-point (PROBE) study - Caravaggio trial - Long-term treatment of cancer associated venous thromboembolism: reduced vs full dose of apixaban: API-CAT STUDY for APIxaban Cancer Associated Thrombosis. Sebastian Szmit is the member of the Polish Cardiac Society & European Society of Cardiology (ESC). He was invited as the reviewer of the 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines. The additional activities include: (1) Cardio-Oncology Council of the European Society of Cardiology; (2) Scientific Steering Committee and Educational Planning Committee of the European Cardio-Oncology Symposium (ECOS); (3) Executive Committee of the Global Cardio-Oncology Summit (GCOS); (4) Education & Training Advisory Committee of the International Cardio-Oncology Society (ICOS); (5)Executive Committee of the International Cardio-Oncology Society (ICOS).